Skip to main content
Genomic Vision logo

Genomic Vision — Investor Relations & Filings

Ticker · GV ISIN · FR0011799907 LEI · 969500UXJNBY1C8Y8471 PA Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2023-11-17 Legal Proceedings Report
Country FR France
Listing PA GV

About Genomic Vision

https://www.genomicvision.com/

Genomic Vision is a biotechnology company specializing in the direct visualization and analysis of single DNA molecules through its proprietary Molecular Combing technology. This platform provides highly accurate characterization of large-scale genomic modifications, offering critical insights into genetic integrity and stability. The company's primary focus is on providing quality control (QC) solutions for the bioproduction and cell and gene therapy markets, ensuring the safety and efficacy of advanced therapeutic products. In drug discovery, its Replication Combing Assay (RCA) is used to assess the effects of compounds on DNA replication. Genomic Vision's tools and services support the entire lifecycle of biopharmaceutical development, from research to production.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Legal Proceedings Report Classification · 99% confidence The document is a press release titled "Genomic Vision announces the opening of a receivership proceedings." It details a legal/financial event (receivership procedure opened by the Commercial Court of Nanterre) and mentions the suspension of share listing. This type of announcement, concerning significant legal or financial distress proceedings that are not standard periodic reports (like 10-K or IR) or routine operational updates, fits best under the category for significant legal proceedings or major corporate events. While 'LTR' (Legal Proceedings Report) is a possibility, the event described is a formal judicial proceeding (receivership) which is a critical, non-routine corporate event. Given the options, this announcement of a major legal/financial restructuring event does not perfectly align with the specific definitions provided. It is not an earnings release (ER), an interim report (IR), or a standard M&A activity (TAR). Since it is a formal announcement regarding a significant legal/judicial action impacting the company's structure and operations, it is most closely related to 'LTR' (Legal Proceedings Report) or, if viewed as a general material event announcement, 'RNS' (Regulatory Filings). However, receivership proceedings are fundamentally legal matters. I will classify it as LTR as it reports on a significant legal proceeding impacting the company's existence, even though it's an announcement rather than a detailed report.
2023-11-17 English
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 99% confidence The document is a press release from Genomic Vision announcing that the Nanterre Commercial Court has opened a 'procédure de redressement judiciaire' (a form of judicial reorganization or receivership) as of November 15, 2023. This type of announcement concerns a significant legal/financial event impacting the company's operations and solvency, but it is not a standard periodic financial report (like 10-K or IR), a management discussion (MDA), or a specific regulatory filing like insider trading (DIRS) or capital change (CAP). It is an announcement regarding a significant legal/financial proceeding. Among the provided codes, 'LTR' (Legal Proceedings Report) is the closest fit, as judicial reorganization proceedings fall under significant legal matters affecting the company's structure and future. It is not a general regulatory filing (RNS) because it is highly specific to a legal/financial status change. It is not an ER, IR, or AR because it does not contain financial results, but rather a legal status update.
2023-11-17 French
Inside Information / News release on accounts, results
Earnings Release Classification · 98% confidence The document is titled "Financial Information for the third quarter of 2023" and provides key financial metrics (Sales, Revenues, Cash position) specifically for the third quarter and the first nine months of 2023. It explicitly states that the figures are unaudited and discusses the company's financial structure and subsequent filing for receivership proceedings. This content structure—a focused release on quarterly financial performance highlights—is characteristic of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim/Quarterly Report (IR), as it focuses on highlights and cash position rather than full financial statements, making ER the most appropriate classification. The document length (7326 chars) is substantial enough to be the release itself, not just an announcement of a report. 9M 2023
2023-11-14 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 100% confidence The document explicitly states it is providing "Information financière du 3 ème trimestre 2023" (Financial information for the 3rd quarter of 2023). It details key financial metrics (revenue, cash position) for the 9-month period ending September 30, 2023, and includes comparative figures. This content structure—a focused release on quarterly/periodical financial results, often highlighting key figures before a full report—aligns perfectly with the definition of an Earnings Release (ER). Although it contains detailed figures, it is presented as a press release announcing the results, not the comprehensive statutory report itself (which would be an IR or 10-K). The mention of future dates for the Q4 and Annual results further confirms this is a periodic update. 9M 2023
2023-11-14 French
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it is a 'Déclaration au titre de l'article 223-16 du règlement général de l'Autorité des marchés financiers' (Declaration under Article 223-16 of the General Regulation of the AMF). This article typically relates to the total number of shares and voting rights, which is a mandatory regulatory disclosure in France. The content provides the total number of shares and theoretical gross voting rights as of a specific date (08.11.2023). This type of mandatory periodic disclosure regarding capital structure and voting rights, especially when referencing specific regulatory articles, fits best under the general 'Regulatory Filings' category (RNS) as there is no specific code for 'Total Shares/Voting Rights Declaration' among the provided options, and it is not a full financial report (10-K, IR) or a management/board change announcement (MANG, DIRS). Given the specific regulatory nature, RNS is the most appropriate fallback.
2023-11-08 French
Informations privilégiées / Autres communiqués
Board/Management Information Classification · 99% confidence The document is titled "Genomic Vision : communiqué relatif aux démissions au sein de la gouvernance" (Genomic Vision: press release regarding resignations within governance). The text explicitly announces the resignation of several members of the Supervisory Board and the Management Board, including the Chairwoman of the Supervisory Board. This content directly relates to changes in the company's board of directors and senior management. According to the definitions, this aligns perfectly with the 'Board/Management Information' category (Code: MANG). The document is a press release announcing management changes, not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2023-11-07 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.